endTB clinical trial offers new shortened drug regimens to treat multidrug-resistant TB

Governments must immediately implement latest WHO guidelines to stop children dying from TB

Recent price reductions to WHO-recommended TB tests and treatment should enable more countries to make these vital medical tools available

MSF calls on negotiators of WHO’s pandemic agreement to establish legally binding norms to ensure just and equitable response to global public health emergencies

Colombia plans to issue compulsory license on HIV drug dolutegravir, expanding access

MSF welcomes Johnson & Johnson's intent not to enforce its patents on key TB drug bedaquiline, paving way for affordable generic versions

Governments must now turn words on paper into practice and take the necessary steps to save more lives of people with TB

Cepheid and Danaher have just announced that they are reducing the price of the Xpert MTB/RIF test by 20% in high-TB-burden countries, from US$9.98 to $7.97 per test. This reduction is a significant step, considering the corporations ...

MSF calls on J&J and Cepheid/Danaher to commit to improving access to key TB drug and test by UNHLM 22 September

MSF urges ViiV to withdraw problematic purchasing conditions hindering access to HIV prevention drug CAB-LA

MSF again called on Gavi to broaden catch-up vaccine coverage for children by waiving co-financing requirements of countries with fragile health systems

MSF calls on Johnson & Johnson not to enforce its secondary patents on TB drug bedaquiline

MSF calls on J&J not to enforce secondary patents on TB drug bedaquiline, to improve global access to this lifesaving medicine

MSF signed onto a letter supporting Colombia’s action to possibly issue a compulsory license to improve access to HIV drug dolutegravir

Pro-access recommendations should serve as a blueprint for the EU to ensure equitable global access to medical tools in a future pandemic

Gavi must do more to vaccinate children up to age five, and waive co-financing requirements of countries with fragile health systems or in humanitarian crisis

MSF welcomes WHA resolution on strengthening diagnostic testing in low- and middle-income countries

MSF warned that access to point-of-care CD4 tests for HIV are under threat because Abbott and Becton Dickinson have decided to stop production

Gilead hikes price while liposomal amphotericin B (L-AmB) for treatment of HIV-related cryptococcal meningitis remains unavailable and unaffordable in countries where it’s most needed

MSF appreciates EC pharma legislation proposal to improve transparency by industry and the granting of compulsory licenses on medicines in the EU.